Pharmaceutical Investing AbbVie Begins Construction on $70 Million Expansion to Further Increase Biologics Manufacturing and R&D Presence in the U.S. 30 September
Pharmaceutical Investing AbbVie Submits Biologics License Application to U.S. FDA for Pivekimab sunirine - an Investigational Antibody-Drug Conjugate to Treat Rare Cancer with Limited Treatment Options 30 September
